New book by Larry Connors Click here Improve your trading - See how
In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and spells the difference between success and failure. The TOP 10, a unique series of market intelligence studies first introduced in 1987, is designed to provide the pharmaceutical industry executives, as well as companies planning to diversify into the pharmaceutical field, with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs.
The study s major objectives include: to establish a comprehensive, factual, annually-updated and cost-effective information base on performance, capabilities, goals and strategies of the world s leading pharmaceutical companies; to help current suppliers realistically assess their financial, marketing and technological capabilities vis- -vis leading competitors; to assist potential market entrants in evaluating prospective acquisitions and joint venture candidates; and to complement organizations internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight.
The study provides an approximately 50-page worldwide strategic overview of the pharmaceutical market, including sales forecast for major product segments (ethical, OTC, generics); key geographic regions (North America, Western Europe, Japan, Eastern Europe, and Latin America); major drug categories, including cardiovascular, gastrointestinal, antibiotics, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, and others. In addition, the report reviews major U.S. and international regulatory, technological, economic, demographic, and social trends with potentially significant impact on the pharmaceutical industry during the next five years, including a discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies.
For each of the Top 10 companies, the report provides: Executive Summary; Business Organization; Senior Management; Facilities and Employees; Technological Know-How; Product Portfolio Analysis; Marketing Tactics; Financial Analysis; R&D Expenditures and Major Programs; Collaborative Arrangements; and Strategic Direction.
Key Topics Covered:
- Business Organization
- Senior Management
- Facilities and Employees
- Technological Know-How
- Product Portfolio Analysis
- Marketing Tactics
- Marketing Tactics
- Financial Analysis
- R&D Expenditures and Major Programs
- Collaborative Arrangements
- Strategic Direction
For more information visit http://www.researchandmarkets.com/research/362366/the_top_10_worlds
CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (from USA) Fax: +353 1 481 1716 (rest of the world) e-mail: press@researchandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
